

**GOVERNMENT OF INDIA
MINISTRY OF CHEMICALS AND FERTILIZERS
DEPARTMENT OF PHARMACEUTICALS**

LOK SABHA
UNSTARRED QUESTION No. 2358
TO BE ANSWERED ON THE 3rd AUGUST, 2021

API Manufacturing

†2358. **SHRI MITESH RAMESHBHAI PATEL (BAKABHAI):**

Will the Minister of **CHEMICALS AND FERTILIZERS** be pleased to state:

- (a) the quantity of Active Pharmaceutical Ingredient (API) manufactured at domestic level including the details thereof;
- (b) the details of efforts made by the Government to promote API manufacturing plants in the country; and
- (c) whether the Government has set any special target for the coming years in this regard and if so, the details thereof?

ANSWER

**MINISTER IN THE MINISTRY OF CHEMICALS & FERTILIZERS
(SHRI MANSUKH MANDAVIYA)**

(a): The quantity of API manufactured domestically is not readily available. However, the size of API and Intermediates market in India is estimated to be Rs. 96,000 crore in FY 2019-20. Further, as per data maintained by Directorate General of Commercial Intelligence and Statistics (DGCIS), the quantity and value of API imported and exported in FY 2020-21 is given below:

	Quantity (In MT)	Value (Rs. In crore)
Imports	3,90,476	28529
Exports	3,24,331	32856

(b) to (c): The Department of Pharmaceuticals is implementing the following three (03) schemes for promoting domestic manufacturing of APIs to ensure their sustainable domestic supply and make India Atma Nirbhar (self-reliant):

(I) Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) In India: The scheme provides for financial incentives to manufacturers selected under the scheme for manufacturing of 41 Key Starting Materials (KSMs)/ Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs). The incentives will be provided on incremental sales to selected participants for a period of 6 years. The total financial outlay of the scheme is Rs. 6,940 crore and the tenure of the scheme is from FY 2020-2021 to 2029-30.

(II) **Scheme for Promotion of Bulk Drug Parks:** The scheme provides for grant-in-aid to three (03) Bulk Drug Parks for creation of Common Infrastructure Facilities (CIF) with a maximum limit of Rs.1000 crore per park or 70% of the project cost of CIF, whichever is less. In case of North Eastern States and Hilly States (Himachal Pradesh, Uttarakhand, Union Territory of Jammu & Kashmir and Union Territory of Ladakh) financial assistance would be 90% of the project cost. The total financial outlay of the Scheme is Rs. 3000 crore and the tenure of the Scheme is from FY 2020-21 to 2024-25.

(III) **Production Linked Incentive Scheme for Pharmaceuticals:** The scheme provides for financial incentives to manufacturers selected under the scheme for manufacturing of Key Starting Materials (KSMs)/ Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) amongst other categories of formulations. The incentives will be provided on incremental sales to selected participants for a period of 6 years. The total financial outlay of the scheme is Rs. 15,000 crore and the tenure of the scheme is from FY 2020-2021 to 2028-29.

The detailed guidelines of the above three schemes are available on the website of the Department under the tab “schemes”.

XXXXX